Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312489 | 0.84 | HCAR2 (0.64) | HCAR2HDAC1 | |
| SCHEMBL12808643 | 0.79 | HCAR2 (0.58) | HCAR2FFAR1LTB4RMMP12NAAA | |
| SCHEMBL4548322 | 0.79 | HCAR2 (0.81) | HCAR2 | |
| SCHEMBL4548317 | 0.78 | HCAR2 (0.83) | HCAR2FFAR1 | |
| SCHEMBL4548396 | 0.76 | HCAR2 (0.55) | HCAR2FFAR1MMP12NAAAMAPT | |
| SCHEMBL4548327 | 0.70 | HCAR2 (0.48) | HCAR2FFAR1MMP12NAAAROCK2 | |
| SCHEMBL7046207 | 0.70 | HDAC1 (0.79) | FFAR1HDAC2MMP12HDAC1 | |
| SCHEMBL4548490 | 0.70 | HCAR2 (0.66) | HCAR2HDAC1 | |
| SCHEMBL4548312 | 0.69 | HCAR2 (0.77) | HCAR2MAPT | |
| SCHEMBL13356363 | 0.68 | MAPT (0.80) | HDAC2HDAC1MAPTHTTROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | HCAR2 2/4885FFAR1 3/4885LTB4R 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.